Skip to main content

Advertisement

Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Fig. 2

Non-responders to anti-PD-1 had lower CD69 and MIP-1β expressing NK cells following PMA + Ionomycin stimulation. Pre-treatment PBMC from melanoma patients who were responders or non-responders to anti-PD-1 therapy were stimulated with PMA + Ionomycin ex vivo, and analyzed by CyTOF. Frequencies of (a) CD69+, (b) MIP-1β+ and (c) CD69+MIP-1β+ NK cells are shown. *p < 0.05

Back to article page